321 related articles for article (PubMed ID: 23806903)
1. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.
Childs-Disney JL; Stepniak-Konieczna E; Tran T; Yildirim I; Park H; Chen CZ; Hoskins J; Southall N; Marugan JJ; Patnaik S; Zheng W; Austin CP; Schatz GC; Sobczak K; Thornton CA; Disney MD
Nat Commun; 2013; 4():2044. PubMed ID: 23806903
[TBL] [Abstract][Full Text] [Related]
2. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
3. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive.
Childs-Disney JL; Hoskins J; Rzuczek SG; Thornton CA; Disney MD
ACS Chem Biol; 2012 May; 7(5):856-62. PubMed ID: 22332923
[TBL] [Abstract][Full Text] [Related]
4. A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.
Jahromi AH; Nguyen L; Fu Y; Miller KA; Baranger AM; Zimmerman SC
ACS Chem Biol; 2013 May; 8(5):1037-43. PubMed ID: 23480597
[TBL] [Abstract][Full Text] [Related]
5. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
6. Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1.
Angelbello AJ; González ÀL; Rzuczek SG; Disney MD
Bioorg Med Chem Lett; 2016 Dec; 26(23):5792-5796. PubMed ID: 27839685
[TBL] [Abstract][Full Text] [Related]
7. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
[TBL] [Abstract][Full Text] [Related]
8. Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts.
Kumar A; Parkesh R; Sznajder LJ; Childs-Disney JL; Sobczak K; Disney MD
ACS Chem Biol; 2012 Mar; 7(3):496-505. PubMed ID: 22252896
[TBL] [Abstract][Full Text] [Related]
9. Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Warf MB; Nakamori M; Matthys CM; Thornton CA; Berglund JA
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18551-6. PubMed ID: 19822739
[TBL] [Abstract][Full Text] [Related]
10. Rationally designed small molecules that target both the DNA and RNA causing myotonic dystrophy type 1.
Nguyen L; Luu LM; Peng S; Serrano JF; Chan HY; Zimmerman SC
J Am Chem Soc; 2015 Nov; 137(44):14180-9. PubMed ID: 26473464
[TBL] [Abstract][Full Text] [Related]
11. Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.
Wong CH; Nguyen L; Peh J; Luu LM; Sanchez JS; Richardson SL; Tuccinardi T; Tsoi H; Chan WY; Chan HY; Baranger AM; Hergenrother PJ; Zimmerman SC
J Am Chem Soc; 2014 Apr; 136(17):6355-61. PubMed ID: 24702247
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy.
Osborne RJ; Lin X; Welle S; Sobczak K; O'Rourke JR; Swanson MS; Thornton CA
Hum Mol Genet; 2009 Apr; 18(8):1471-81. PubMed ID: 19223393
[TBL] [Abstract][Full Text] [Related]
13. MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1.
Dansithong W; Paul S; Comai L; Reddy S
J Biol Chem; 2005 Feb; 280(7):5773-80. PubMed ID: 15546872
[TBL] [Abstract][Full Text] [Related]
14. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
[TBL] [Abstract][Full Text] [Related]
15. A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways.
Benhamou RI; Angelbello AJ; Wang ET; Disney MD
Cell Chem Biol; 2020 Feb; 27(2):223-231.e4. PubMed ID: 31981476
[TBL] [Abstract][Full Text] [Related]
16. Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model.
Angelbello AJ; Rzuczek SG; Mckee KK; Chen JL; Olafson H; Cameron MD; Moss WN; Wang ET; Disney MD
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7799-7804. PubMed ID: 30926669
[TBL] [Abstract][Full Text] [Related]
17. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.
Lin X; Miller JW; Mankodi A; Kanadia RN; Yuan Y; Moxley RT; Swanson MS; Thornton CA
Hum Mol Genet; 2006 Jul; 15(13):2087-97. PubMed ID: 16717059
[TBL] [Abstract][Full Text] [Related]
18. Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1.
Childs-Disney JL; Parkesh R; Nakamori M; Thornton CA; Disney MD
ACS Chem Biol; 2012 Dec; 7(12):1984-93. PubMed ID: 23130637
[TBL] [Abstract][Full Text] [Related]
19. Muscleblind-like 1 knockout mice reveal novel splicing defects in the myotonic dystrophy brain.
Suenaga K; Lee KY; Nakamori M; Tatsumi Y; Takahashi MP; Fujimura H; Jinnai K; Yoshikawa H; Du H; Ares M; Swanson MS; Kimura T
PLoS One; 2012; 7(3):e33218. PubMed ID: 22427994
[TBL] [Abstract][Full Text] [Related]
20. RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy.
Sobczak K; Wheeler TM; Wang W; Thornton CA
Mol Ther; 2013 Feb; 21(2):380-7. PubMed ID: 23183533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
